Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial

BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho. METH...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of acquired immune deficiency syndromes (1999) 2020-11, Vol.85 (3), p.280-291
Hauptverfasser: Tukei, Betty B., Fatti, Geoffrey, Tiam, Appolinaire, Ngorima-Mabhena, Nicoletta, Tukei, Vincent J., Tshabalala, Itumeleng, Sejana, Veronica M., Muzenda, Trish, Mokoroane, Lincoln M., Sehlabo, Lebelang, Maotoe, Thapelo, Mirembe, Justine K., Membe, Ian, Akpan, Francis, Maile, Khotso, Faturiyele, Iyiola, Xulu, Thembi, Minior, Thomas, Sanne, Ian, Chasela, Charles
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 291
container_issue 3
container_start_page 280
container_title Journal of acquired immune deficiency syndromes (1999)
container_volume 85
creator Tukei, Betty B.
Fatti, Geoffrey
Tiam, Appolinaire
Ngorima-Mabhena, Nicoletta
Tukei, Vincent J.
Tshabalala, Itumeleng
Sejana, Veronica M.
Muzenda, Trish
Mokoroane, Lincoln M.
Sehlabo, Lebelang
Maotoe, Thapelo
Mirembe, Justine K.
Membe, Ian
Akpan, Francis
Maile, Khotso
Faturiyele, Iyiola
Xulu, Thembi
Minior, Thomas
Sanne, Ian
Chasela, Charles
description BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho. METHODS:Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.govNCT03438370). RESULTS:A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI)−1.6% to 1.5%], adjusted RD = −1.3% (95% CI−3.0% to 0.5%), and adjusted RD = −1.2% (95% CI−2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI0.98 to 1.01) and RR = 1.00 (95% CI0.98 to 1.01), respectively. CONCLUSIONS:There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model.
doi_str_mv 10.1097/QAI.0000000000002439
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2424102350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2507461342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5039-b78c103bbbcf429f6fe747a515f5851f8250ef2db4711177c67a3b0b5ed811e3</originalsourceid><addsrcrecordid>eNqFks1uEzEUhS0EoiXwBghZYsPGxb_zw26aAo2UUFEitiPPzHXj4hkHe4aovBfvh9MUhLoo3tjW_c65Vz5G6CWjJ4yW-dvP1eKE_rO4FOUjdMxKKUleFPJxOiuuiGRCHaFnMV5TyjIpy6foSPAsUzKjx-jXegfuB5CVH8YNvpjG1vcQsTd47vt-Gux4Q051hA6fWWMgwDBaPabrynfgbsHV5Ebb3-rPbNzCEO1wtS9Ul2tcpcIV_jLqxgE-X3wli8FAuzeouqSL2A54CdGPG_8OV3jupjhCIJd66Hxvfybukx9s0gTrQxoGr4PV7jl6YrSL8OJun6H1h_fr-TlZXnxczKslaRUVJWnyomVUNE3TGslLkxnIZa4VU0YVipmCKwqGd43MGWN53ma5Fg1tFHQFYyBm6M3Bdhv89wniWPc2tuCcHsBPseaSS0a5SM1m6PU99NpPYUjD1alJLjMmJH-QkkqyMitTXDMkD1QbfIwBTL0Nttfhpma03mdfp-zr-9kn2as786npofsr-hN2AooDsPMuPXL85qYdhHoD2o2b_3nLB6TpY_FMCEk45ZQxyijZKzPxGwihyus</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454196941</pqid></control><display><type>article</type><title>Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Free E- Journals</source><creator>Tukei, Betty B. ; Fatti, Geoffrey ; Tiam, Appolinaire ; Ngorima-Mabhena, Nicoletta ; Tukei, Vincent J. ; Tshabalala, Itumeleng ; Sejana, Veronica M. ; Muzenda, Trish ; Mokoroane, Lincoln M. ; Sehlabo, Lebelang ; Maotoe, Thapelo ; Mirembe, Justine K. ; Membe, Ian ; Akpan, Francis ; Maile, Khotso ; Faturiyele, Iyiola ; Xulu, Thembi ; Minior, Thomas ; Sanne, Ian ; Chasela, Charles</creator><creatorcontrib>Tukei, Betty B. ; Fatti, Geoffrey ; Tiam, Appolinaire ; Ngorima-Mabhena, Nicoletta ; Tukei, Vincent J. ; Tshabalala, Itumeleng ; Sejana, Veronica M. ; Muzenda, Trish ; Mokoroane, Lincoln M. ; Sehlabo, Lebelang ; Maotoe, Thapelo ; Mirembe, Justine K. ; Membe, Ian ; Akpan, Francis ; Maile, Khotso ; Faturiyele, Iyiola ; Xulu, Thembi ; Minior, Thomas ; Sanne, Ian ; Chasela, Charles ; for EQUIP Health</creatorcontrib><description>BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho. METHODS:Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.govNCT03438370). RESULTS:A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI)−1.6% to 1.5%], adjusted RD = −1.3% (95% CI−3.0% to 0.5%), and adjusted RD = −1.2% (95% CI−2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI0.98 to 1.01) and RR = 1.00 (95% CI0.98 to 1.01), respectively. CONCLUSIONS:There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/QAI.0000000000002439</identifier><identifier>PMID: 32665460</identifier><language>eng</language><publisher>United States: JAIDS Journal of Acquired Immune Deficiency Syndromes</publisher><subject>Adolescent ; Adult ; Adults ; AIDS/HIV ; Anti-HIV Agents - economics ; Anti-HIV Agents - therapeutic use ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Cluster Analysis ; Clustering ; Confidence intervals ; Dispensing ; Drug Prescriptions ; Female ; Health Care Costs ; Health Facilities ; Health Services Accessibility ; HIV ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Lesotho ; Male ; Middle Aged ; Patient Compliance ; Retention ; Risk management ; Viral Load ; Young Adult</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2020-11, Vol.85 (3), p.280-291</ispartof><rights>JAIDS Journal of Acquired Immune Deficiency Syndromes</rights><rights>Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright Lippincott Williams &amp; Wilkins Ovid Technologies Nov 1, 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5039-b78c103bbbcf429f6fe747a515f5851f8250ef2db4711177c67a3b0b5ed811e3</citedby><cites>FETCH-LOGICAL-c5039-b78c103bbbcf429f6fe747a515f5851f8250ef2db4711177c67a3b0b5ed811e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;NEWS=n&amp;CSC=Y&amp;PAGE=fulltext&amp;D=ovft&amp;AN=00126334-202011010-00006$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,777,781,4595,27905,27906,65212</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32665460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tukei, Betty B.</creatorcontrib><creatorcontrib>Fatti, Geoffrey</creatorcontrib><creatorcontrib>Tiam, Appolinaire</creatorcontrib><creatorcontrib>Ngorima-Mabhena, Nicoletta</creatorcontrib><creatorcontrib>Tukei, Vincent J.</creatorcontrib><creatorcontrib>Tshabalala, Itumeleng</creatorcontrib><creatorcontrib>Sejana, Veronica M.</creatorcontrib><creatorcontrib>Muzenda, Trish</creatorcontrib><creatorcontrib>Mokoroane, Lincoln M.</creatorcontrib><creatorcontrib>Sehlabo, Lebelang</creatorcontrib><creatorcontrib>Maotoe, Thapelo</creatorcontrib><creatorcontrib>Mirembe, Justine K.</creatorcontrib><creatorcontrib>Membe, Ian</creatorcontrib><creatorcontrib>Akpan, Francis</creatorcontrib><creatorcontrib>Maile, Khotso</creatorcontrib><creatorcontrib>Faturiyele, Iyiola</creatorcontrib><creatorcontrib>Xulu, Thembi</creatorcontrib><creatorcontrib>Minior, Thomas</creatorcontrib><creatorcontrib>Sanne, Ian</creatorcontrib><creatorcontrib>Chasela, Charles</creatorcontrib><creatorcontrib>for EQUIP Health</creatorcontrib><title>Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho. METHODS:Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.govNCT03438370). RESULTS:A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI)−1.6% to 1.5%], adjusted RD = −1.3% (95% CI−3.0% to 0.5%), and adjusted RD = −1.2% (95% CI−2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI0.98 to 1.01) and RR = 1.00 (95% CI0.98 to 1.01), respectively. CONCLUSIONS:There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - economics</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Cluster Analysis</subject><subject>Clustering</subject><subject>Confidence intervals</subject><subject>Dispensing</subject><subject>Drug Prescriptions</subject><subject>Female</subject><subject>Health Care Costs</subject><subject>Health Facilities</subject><subject>Health Services Accessibility</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Lesotho</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Compliance</subject><subject>Retention</subject><subject>Risk management</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks1uEzEUhS0EoiXwBghZYsPGxb_zw26aAo2UUFEitiPPzHXj4hkHe4aovBfvh9MUhLoo3tjW_c65Vz5G6CWjJ4yW-dvP1eKE_rO4FOUjdMxKKUleFPJxOiuuiGRCHaFnMV5TyjIpy6foSPAsUzKjx-jXegfuB5CVH8YNvpjG1vcQsTd47vt-Gux4Q051hA6fWWMgwDBaPabrynfgbsHV5Ebb3-rPbNzCEO1wtS9Ul2tcpcIV_jLqxgE-X3wli8FAuzeouqSL2A54CdGPG_8OV3jupjhCIJd66Hxvfybukx9s0gTrQxoGr4PV7jl6YrSL8OJun6H1h_fr-TlZXnxczKslaRUVJWnyomVUNE3TGslLkxnIZa4VU0YVipmCKwqGd43MGWN53ma5Fg1tFHQFYyBm6M3Bdhv89wniWPc2tuCcHsBPseaSS0a5SM1m6PU99NpPYUjD1alJLjMmJH-QkkqyMitTXDMkD1QbfIwBTL0Nttfhpma03mdfp-zr-9kn2as786npofsr-hN2AooDsPMuPXL85qYdhHoD2o2b_3nLB6TpY_FMCEk45ZQxyijZKzPxGwihyus</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Tukei, Betty B.</creator><creator>Fatti, Geoffrey</creator><creator>Tiam, Appolinaire</creator><creator>Ngorima-Mabhena, Nicoletta</creator><creator>Tukei, Vincent J.</creator><creator>Tshabalala, Itumeleng</creator><creator>Sejana, Veronica M.</creator><creator>Muzenda, Trish</creator><creator>Mokoroane, Lincoln M.</creator><creator>Sehlabo, Lebelang</creator><creator>Maotoe, Thapelo</creator><creator>Mirembe, Justine K.</creator><creator>Membe, Ian</creator><creator>Akpan, Francis</creator><creator>Maile, Khotso</creator><creator>Faturiyele, Iyiola</creator><creator>Xulu, Thembi</creator><creator>Minior, Thomas</creator><creator>Sanne, Ian</creator><creator>Chasela, Charles</creator><general>JAIDS Journal of Acquired Immune Deficiency Syndromes</general><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><general>Lippincott Williams &amp; Wilkins Ovid Technologies</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20201101</creationdate><title>Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial</title><author>Tukei, Betty B. ; Fatti, Geoffrey ; Tiam, Appolinaire ; Ngorima-Mabhena, Nicoletta ; Tukei, Vincent J. ; Tshabalala, Itumeleng ; Sejana, Veronica M. ; Muzenda, Trish ; Mokoroane, Lincoln M. ; Sehlabo, Lebelang ; Maotoe, Thapelo ; Mirembe, Justine K. ; Membe, Ian ; Akpan, Francis ; Maile, Khotso ; Faturiyele, Iyiola ; Xulu, Thembi ; Minior, Thomas ; Sanne, Ian ; Chasela, Charles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5039-b78c103bbbcf429f6fe747a515f5851f8250ef2db4711177c67a3b0b5ed811e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - economics</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Cluster Analysis</topic><topic>Clustering</topic><topic>Confidence intervals</topic><topic>Dispensing</topic><topic>Drug Prescriptions</topic><topic>Female</topic><topic>Health Care Costs</topic><topic>Health Facilities</topic><topic>Health Services Accessibility</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Lesotho</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Compliance</topic><topic>Retention</topic><topic>Risk management</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tukei, Betty B.</creatorcontrib><creatorcontrib>Fatti, Geoffrey</creatorcontrib><creatorcontrib>Tiam, Appolinaire</creatorcontrib><creatorcontrib>Ngorima-Mabhena, Nicoletta</creatorcontrib><creatorcontrib>Tukei, Vincent J.</creatorcontrib><creatorcontrib>Tshabalala, Itumeleng</creatorcontrib><creatorcontrib>Sejana, Veronica M.</creatorcontrib><creatorcontrib>Muzenda, Trish</creatorcontrib><creatorcontrib>Mokoroane, Lincoln M.</creatorcontrib><creatorcontrib>Sehlabo, Lebelang</creatorcontrib><creatorcontrib>Maotoe, Thapelo</creatorcontrib><creatorcontrib>Mirembe, Justine K.</creatorcontrib><creatorcontrib>Membe, Ian</creatorcontrib><creatorcontrib>Akpan, Francis</creatorcontrib><creatorcontrib>Maile, Khotso</creatorcontrib><creatorcontrib>Faturiyele, Iyiola</creatorcontrib><creatorcontrib>Xulu, Thembi</creatorcontrib><creatorcontrib>Minior, Thomas</creatorcontrib><creatorcontrib>Sanne, Ian</creatorcontrib><creatorcontrib>Chasela, Charles</creatorcontrib><creatorcontrib>for EQUIP Health</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tukei, Betty B.</au><au>Fatti, Geoffrey</au><au>Tiam, Appolinaire</au><au>Ngorima-Mabhena, Nicoletta</au><au>Tukei, Vincent J.</au><au>Tshabalala, Itumeleng</au><au>Sejana, Veronica M.</au><au>Muzenda, Trish</au><au>Mokoroane, Lincoln M.</au><au>Sehlabo, Lebelang</au><au>Maotoe, Thapelo</au><au>Mirembe, Justine K.</au><au>Membe, Ian</au><au>Akpan, Francis</au><au>Maile, Khotso</au><au>Faturiyele, Iyiola</au><au>Xulu, Thembi</au><au>Minior, Thomas</au><au>Sanne, Ian</au><au>Chasela, Charles</au><aucorp>for EQUIP Health</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>85</volume><issue>3</issue><spage>280</spage><epage>291</epage><pages>280-291</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><abstract>BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho. METHODS:Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.govNCT03438370). RESULTS:A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI)−1.6% to 1.5%], adjusted RD = −1.3% (95% CI−3.0% to 0.5%), and adjusted RD = −1.2% (95% CI−2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI0.98 to 1.01) and RR = 1.00 (95% CI0.98 to 1.01), respectively. CONCLUSIONS:There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model.</abstract><cop>United States</cop><pub>JAIDS Journal of Acquired Immune Deficiency Syndromes</pub><pmid>32665460</pmid><doi>10.1097/QAI.0000000000002439</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1525-4135
ispartof Journal of acquired immune deficiency syndromes (1999), 2020-11, Vol.85 (3), p.280-291
issn 1525-4135
1944-7884
language eng
recordid cdi_proquest_miscellaneous_2424102350
source MEDLINE; Journals@Ovid LWW Legacy Archive; Free E- Journals
subjects Adolescent
Adult
Adults
AIDS/HIV
Anti-HIV Agents - economics
Anti-HIV Agents - therapeutic use
Antiretroviral agents
Antiretroviral drugs
Antiretroviral therapy
Cluster Analysis
Clustering
Confidence intervals
Dispensing
Drug Prescriptions
Female
Health Care Costs
Health Facilities
Health Services Accessibility
HIV
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Lesotho
Male
Middle Aged
Patient Compliance
Retention
Risk management
Viral Load
Young Adult
title Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T04%3A17%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Twelve-Month%20Outcomes%20of%20Community-Based%20Differentiated%20Models%20of%20Multimonth%20Dispensing%20of%20ART%20Among%20Stable%20HIV-Infected%20Adults%20in%20Lesotho:%20A%20Cluster-Randomized%20Noninferiority%20Trial&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Tukei,%20Betty%20B.&rft.aucorp=for%20EQUIP%20Health&rft.date=2020-11-01&rft.volume=85&rft.issue=3&rft.spage=280&rft.epage=291&rft.pages=280-291&rft.issn=1525-4135&rft.eissn=1944-7884&rft_id=info:doi/10.1097/QAI.0000000000002439&rft_dat=%3Cproquest_cross%3E2507461342%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2454196941&rft_id=info:pmid/32665460&rfr_iscdi=true